Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers

Joshi J. Alumkal; James G. Herman

doi:10.1158/2159-8290.CD-12-0392

Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers

Joshi J. Alumkal, James G. Herman

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

This issue of Cancer Discovery features an article that describes distinct epigenetic mechanisms that operate in TMPRSS2-ERG fusion-negative prostate cancers. This finding clarifies molecular features of these TMPRSS2-ERG fusion-negative tumors and may have implications for how to treat this prostate cancer subtype.

Original language	English (US)
Pages (from-to)	979-981
Number of pages	3
Journal	Cancer discovery
Volume	2
Issue number	11
DOIs	https://doi.org/10.1158/2159-8290.CD-12-0392
State	Published - Nov 2012
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.1158/2159-8290.CD-12-0392

Cite this

@article{a21b7a3904cf4ba1ba79ceef4b407aef,

title = "Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers",

abstract = "This issue of Cancer Discovery features an article that describes distinct epigenetic mechanisms that operate in TMPRSS2-ERG fusion-negative prostate cancers. This finding clarifies molecular features of these TMPRSS2-ERG fusion-negative tumors and may have implications for how to treat this prostate cancer subtype.",

author = "Alumkal, {Joshi J.} and Herman, {James G.}",

year = "2012",

month = nov,

doi = "10.1158/2159-8290.CD-12-0392",

language = "English (US)",

volume = "2",

pages = "979--981",

journal = "Cancer discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "11",

}

TY - JOUR

T1 - Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers

AU - Alumkal, Joshi J.

AU - Herman, James G.

PY - 2012/11

Y1 - 2012/11

N2 - This issue of Cancer Discovery features an article that describes distinct epigenetic mechanisms that operate in TMPRSS2-ERG fusion-negative prostate cancers. This finding clarifies molecular features of these TMPRSS2-ERG fusion-negative tumors and may have implications for how to treat this prostate cancer subtype.

AB - This issue of Cancer Discovery features an article that describes distinct epigenetic mechanisms that operate in TMPRSS2-ERG fusion-negative prostate cancers. This finding clarifies molecular features of these TMPRSS2-ERG fusion-negative tumors and may have implications for how to treat this prostate cancer subtype.

UR - http://www.scopus.com/inward/record.url?scp=84870003550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870003550&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-12-0392

DO - 10.1158/2159-8290.CD-12-0392

M3 - Article

C2 - 23148372

AN - SCOPUS:84870003550

SN - 2159-8274

VL - 2

SP - 979

EP - 981

JO - Cancer discovery

JF - Cancer discovery

IS - 11

ER -

Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this